Lesion Size Measurement During Gastrointestinal Endoscopies
Recruiting · NCT07770425 · Observational (researchers observe without assigning treatment) · Lead sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
View the official record on ClinicalTrials.gov →What this trial is about
The goal of this prospective observational study is to assess the accuracy and reliability of laser readings obtained through AccuMeasure, in comparison to other measurements performed by gastroenterologists. AccuMeasure is a novel technology, that has emerged as a promising tool for measuring polyps and lesions during colonoscopies. The system employs laser-based measurements, enabling precise determination of lesion size, depth, and extent. The main hypotheses this study aims to evaluate are: * AccuMeasure technology, with its precise laser measurements, will demonstrate superior accuracy and reliability in assessing lesion size of pathologies encountered during endoscopies, when compared to other endoscopic scoring methods. * AccuMeasure measurements will show strong construct validity by correlating significantly with endoscopic subscores, symptomatic remission (CD PRO2 \<8, partial mayo score), and fecal calprotectin values.
Who can take part
Inclusion criteria
- Adult patients (18 years and older)
- Patients undergoing gastrointestinal endoscopy procedures
Exclusion criteria
- Minors: Patients under 18 years of age.
- Patients who do not provide informed consent.
- Patients undergoing endoscopy on an emergency basis (defined as urgent diagnostic or therapeutic endoscopy performed on the gastrointestinal (GI) tract to address potentially life-threatening conditions or severe symptoms that require immediate medical attention).
- An American Society of Anesthesiologists (ASA) physical status classification greater than 3.
Where it is running
1 location listed.
- Centre Hospitalier de l'Université de Montréal - Montreal, Quebec, Canada